# 1 Loss of GFAP causes optico-retinal dysplasia and vision impairment

Menachem Viktor Khamo Sarusie <sup>1,2</sup>, Cecilia Rönnbäck <sup>3</sup>, Cathrine Jespersgaard <sup>1</sup>, Sif
Baungaard <sup>2</sup>, Yeasmeen Ali <sup>4</sup>, Line Kessel <sup>3,5</sup>, Søren Tvorup Christensen <sup>4</sup>, Karen BrøndumNielsen <sup>1</sup>, Kjeld Møllgård <sup>2</sup>, Thomas Rosenberg <sup>3</sup>, Lars Allan Larsen <sup>2</sup>\*, and Karen Grønskov
<sup>1</sup>\*.

6

<sup>1</sup> Kennedy Center, Department of Clinical Genetics, Rigshospitalet, University of
Copenhagen, 2600 Glostrup, Denmark; <sup>2</sup> Department of Cellular and Molecular Medicine,
University of Copenhagen, Copenhagen, Denmark; <sup>3</sup> Department of Ophthalmology,
Rigshospitalet-Glostrup, University of Copenhagen, 2600 Glostrup, Denmark; <sup>4</sup> Department
of Biology, University of Copenhagen, Copenhagen, Denmark; <sup>5</sup> Department of Clinical
Medicine, University of Copenhagen, Copenhagen, Denmark.

13

14 \* Corresponding authors:

15 Karen Grønskov, Kennedy Center, Department of Clinical Genetics, Rigshospitalet,

16 University of Copenhagen, 2600 Glostrup, Denmark., e-mail: Karen.Groenskov@regionh.dk

17 Lars Allan Larsen, Department of Cellular and Molecular Medicine, University of

18 Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark, e-mail: larsal@sund.ku.dk

19 Keywords: GFAP, Hereditary, optico-retinal dysplasia, Alexander's disease.

20

21

22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 23 ABSTRACT

Diagnosis of genetic diseases has taken tremendous steps forward since the human genome 24 25 project and technical advancements such as next generation sequencing. However, in the past years it has become evident that the classical "one gene - one phenotype" model is 26 insufficient to encompass the intricacies of human genetics. Examples are emerging that 27 28 variants in a gene can cause quite diverging phenotypes depending on the specific location in the gene or on the specific type of variant. In the era of precision medicine this is important 29 knowledge, both when interpreting genomic data, but also when designing treatment 30 31 strategies.

Gain-of-function variants in *GFAP* leads to protein aggregation and is the cause of the severe
neurodegenerative disorder Alexander Disease (AxD), while loss of GFAP function has been
considered benign. Here, we report a loss-of-function variant in *GFAP* as the cause of opticoretinal dysplasia and vision impairment in a six-generation family.

36 Whole genome sequencing analysis of family members with gliosis of the optic nerve head 37 and visual impairment revealed a frameshift variant in **GFAP** (c.928dup, p.(Met310Asnfs\*113)) segregating with disease. Analysis of human embryonic tissues 38 39 revealed strong expression of GFAP in retinal neural progenitors. A zebrafish model verified that c.928dup does not result in extensive GFAP protein aggregation and zebrafish gfap loss-40 of-function mutants showed vision impairment and retinal dysplasia, characterized by a 41 significant loss of Müller glia cells and photoreceptor cells. 42

43 Our findings show how different mutational mechanisms can cause diverging phenotypes and
44 reveal a novel function of GFAP in human eye development.

# 45 INTRODUCTION

Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein, expressed in 46 astrocytes of the adult central nervous system (CNS) and retina of mammals<sup>1,2</sup>. In the 47 developing human brain, GFAP is expressed in radial glial cells (RGCs) from 6 weeks post 48 conception (wpc) and in astrocytes from 14 wpc<sup>3</sup>. The expression of GFAP in the developing 49 retina is less well studied. Early immunohistochemical analyses did not reveal GFAP 50 expression in retinal tissue of mouse embryos (E12-E20)<sup>4</sup>, while a more recent study, based 51 on embryos obtained from S. canicula (small-spotted catshark), identified GFAP expression 52 in RNPs at early developmental stages and in Müller glia cells (MGCs) at later stages<sup>5</sup>. 53 However, upregulation of GFAP expression in MGCs occurs in all vertebrate species in 54 response to eye injury and disease. In fish and chicken, MGCs serve as a source for neural 55 progenitors including photoreceptors and a scaffold for the progenitors to migrate upon to 56 regenerating retina layers <sup>6-10</sup>. Despite expression of GFAP in RNPs and MGCs in some 57 58 species, the role of GFAP in retina development remains poorly understood.

Rare missense variants within GFAP cause Alexander disease (AxD, OMIM #203450) - an 59 autosomal dominant inherited severe leukodystrophy with variable onset ranging from infant 60 to adult life<sup>11</sup>. AxD is characterized by Rosenthal fibers (RFs), which are dense inclusions 61 within astrocytes of the forebrain and/or hindbrain, caused by aggregation and accumulation 62 of GFAP<sup>12,13</sup>. The majority of GFAP variants identified in AxD patients are de novo 63 heterozygous missense variants, while a few cases with variants leading to in-frame protein 64 alterations have been reported<sup>13</sup>. A single patient, carrying a GFAP nonsense variant 65 (p.E312\*), with a mild form of AxD has been reported<sup>14</sup>. The apparent absence of loss-of-66 function GFAP variants in patients, combined with supporting evidence from mouse models, 67 suggest that AxD is caused by GFAP toxicity through a gain-of-function mechanism<sup>12,15</sup>. 68

Recent research in rodent models of AxD proposes that suppression of GFAP expression, through *Gfap*-targeted antisense oligonucleotides, is a promising therapeutic approach to reverse the disease progression in  $AxD^{16,17}$ . With these exciting and encouraging results in mind, it is important to delineate the normal function of GFAP and any possible side effects from suppression of GFAP.

Here, we report the discovery of a rare form of autosomal dominant optico-retinal disorder
segregating in a six-generation Danish family. Genetic analysis led to identification of a
heterozygous frameshift variant of *GFAP* segregating with the disease in the family.

Analysis of human embryonic tissues and zebrafish *gfap* mutants confirmed that GFAP plays

an important role in retinal development and that loss of GFAP can cause visual impairment.

# 79 **RESULTS**

# Identification of a family with inherited dysplasia of the optic nerve head with retinal involvement

A six-generation Danish family with low vision was discovered and followed during a period
of 35 years (Fig. 1a). Clinical examination was performed in seven family members (IV-1,
IV-6, V-1, V-3, V-7, VI-2, and VI-4) with best corrected visual acuity (BCVA) from normal
to low vision. Table S1 summarizes clinical and genetic data for four individuals (IV-6 (nonpenetrant), V-1, V-3, and V-7) and figure 1b shows OCT of three individuals (V-1, V-3, and
V-7) and optic nerve head photographs of all seven individuals.

Three family members with macular involvement (IV-1, V-3 and V-7) were visually impaired (20/60 and 20/120 at latest follow-up) whereas vision was normal or slightly subnormal in family members without macular involvement. The earliest examinations of family members were carried out at age six and seven years. The condition was largely stationary in individuals followed through decades.

93 Noticeable clinical heterogeneity was present. The fundoscopic phenotype showed varied 94 degrees of gliosis of the optic nerve head resulting in a dome-shaped pellucid epiretinal veil and blurring of the disc margins. Three of the affected individuals (IV-1, V-3, and V-7) 95 96 presented a massive glia-like mass covering the optic disc resembling pseudopapilledema. The mass extended along both arteries and veins, which demonstrated sheating/gliosis, a 97 cork-shrew tortuous appearance, and punctuate and splinter hemorrhages. Subretinal fluid 98 was observed. The papillo-macular area including the fovea showed atrophy of the pigment 99 epithelium (Fig. 1b, Table S1). No retinal dragging was observed in any of the affected 100 individuals. Individuals V-3 and V-7 with macular atrophy had central scotomas as measured 101 102 with Goldmann perimetry; color vision and dark- and light-adapted full-field ERG, however, were normal. OCT confirmed the abnormal morphology of the optic disc in individuals V-3 103 and V-7 with the epiretinal glial-like mass extended temporally to the macular region, which 104 showed disorganized inner retinal layering (Fig. 1b). The tissue complex measured as much 105 as 1.3 mm in height in the subject with the most excessive glial growth. In the fovea of 106 107 individuals V-3 and V-7 the retina was disorganized with clumped hyperpigmentations and atrophic retinal pigment epithelium (Fig. 1b), which probably explains the poor vision. 108 Fluorescein angiography of individual V-7 at the age of 18 showed that the epi-papillary glial 109 mass was richly vascularized, which continued into the papillo-macular area following the 110 nerve fiber pattern (not shown). Early and late profuse capillary leakage was present at the 111 posterior pole and in the foveal area. All the examined individuals were in good health 112 without signs of any systemic disease. 113

# 114 Identification of a rare variant in the *GFAP* gene

Whole genome sequencing (WGS) with subsequent filtering of variants showed that three
affected individuals (V-1, V-3 and V-7) were all heterozygous for five rare coding variants,
which were not present in an unaffected individual (IV-4) (Fig. 1a, Table S2). Two of the five

variants were synonymous (PEMT p.Pro19= and OR10H2 p.Thr116=), not predicted to affect 118 119 splicing using the spice predictors in Alamut Visual, and were not further analysed. Neither *PEMT* nor *OR10H2* are associated with a human phenotype. Two variants were missense 120 121 variants (GAS2L2 p.Pro288Leu and SOST p.Ala28Val). Biallelic variants in GAS2L2 are associated with primary ciliary dyskinesia (OMIM 618449)<sup>18</sup>; GAS2L2 p.Pro288Leu was 122 classified as VUS (variant of unknown significance) following ACMG guidelines<sup>19</sup> and 123 ClinGenome webpage<sup>20</sup>. Monoallelic variants in *SOST* are associated with Craniodiaphyseal 124 dysplasia (OMIM 122860)<sup>21</sup> and biallelic variants are associated with Sclerosteosis 1 (OMIM 125 269500)<sup>22</sup>. According to ACMG guidelines, the variant is classified as VUS, but the presence 126 127 of 19 alleles out of 251433 in gnomAD v2.1.1 database, would be considered too high for a severe dominant disease with onset in childhood. We therefore considered it unlikely that 128 129 these four variants were the cause of retinal dysplasia in the family.

The fifth variant, NC\_000017.11:g.44911435dup (NM\_002055.5:c.928dup) within the 130 131 coding region of GFAP is predicted to result in a frameshift at codon 310, and termination after incorporation of 112 aberrant amino acids (p.Met310Asnfs\*113) (wild type GFAP is 132 431-438 aa). Furthermore, analysis of additional family members IV-6, V-8, VI-3, and VI-4 133 showed that the variant in GFAP segregated with the optico-retinal phenotype in the family, 134 although one case of non-penetrance was observed (individual IV-6). The variant is not 135 present in the 125,748 exomes and 76,156 genomes of Genome Aggregation Database 136 (gnomAD v.2.1.1) and it is classified as "likely pathogenic" according to ACMG guidelines 137 (PVS1\_moderat, PM2\_supportive, PP1\_strong). 138

Together, our clinical and genetic analysis show that the GFAP variant p.Met310Asnfs\*113
cause a novel human eye phenotype and suggest that GFAP might be involved in human
retinal development.

#### 142 Expression of GFAP in retinal neural progenitors of the developing human eye

To determine if GFAP is involved in human retinal development, we performed immunohistochemical analysis of human embryonic and fetal tissue sections at different stages of eye development. We observed strong expression of GFAP in retinal neural progenitors (RNPs) as early as 35 days post conception, dpc (Fig. 2a-b).

At 51 dpc we observed strong GFAP expression in early RNPs near the ciliary body and gradually weaker expression in more differentiated RNPs in regions closer to the optic nerve papilla (Fig. 2c). Immunostaining of a 13 weeks post conception eye showed very weak GFAP expression in Müller Glia Cells, but strong expression in astrocytes entering the retina from the optic nerve (Fig. 2d-f).

# 152 The c.928dup variant does not result in extensive GFAP protein aggregation

A hallmark of AxD pathology is the presence of RFs, which are cytoplasmic protein 153 aggregates in astrocytes of the brain, formed predominantly due to gain of function missense 154 variants in the GFAP gene<sup>12,13</sup>. To assess potential protein aggregation properties of the 155 p.Met310Asnfs\*113 GFAP variant, we constructed plasmids, capable of expressing GFP-156 tagged human wild-type (WT) or p.Met310Asnfs\*113 GFAP variant under the control of a 157 zebrafish gfap promoter. The constructs were injected into fertilized zebrafish oocytes and 158 the resulting number of GFAP protein aggregates within the brain and spinal cord was 159 quantified<sup>23</sup>. For comparison, we injected a construct with a previously reported GFAP 160 missense variant (p.Arg79Cys) associated with AxD and known to cause aggregation in the 161 zebrafish *in vivo* assay<sup>11,23</sup>. As expected, the p.Arg79Cys GFAP variant resulted in extensive 162 protein aggregation in the spinal cord and brain compared to the WT GFAP (Fig. 3a, 3a'). In 163 contrast, we found that there was no significant difference in the number of aggregates 164 165 between WT and p.Met310Asnfs\*113 GFAP variant (Fig. 3a, 3a'). Western blot (WB) analysis confirmed the presence of p.Met310Asnfs\*113 protein indicating that the absence of
GFAP aggregates was not due to extensive protein degradation *in vivo* (Fig. 3b). These
results suggest that the disorder observed in affected individuals with the c.928dup *GFAP*allele has a different pathological mechanism than that seen in AxD patients.

# 170 Silencing of *gfap* expression in zebrafish causes a retinal dysplasia-like phenotype.

To investigate whether GFAP loss of function disrupts eye development in vivo, we used the 171 CRISPR/Cas9 system to silence gfap expression and diminish potential genetic 172 compensation<sup>24</sup>. We identified and characterised two phenotypically similar alleles with a 173 460 bp  $(gfap^{4460})$  and 560 bp deletion  $(gfap^{4560ins24})$ , respectively, spanning the TATA-box 174 among other elements in the gfap promoter region as well as the start-codon in the first exon 175 176 (Fig. S1). These gfap promoter-less mutants showed an expected reduction in gfap mRNA and protein expression levels found in the optic nerve fibre layer, MGCs processes and 177 endfeet (Fig. S2). The results outlined below are generated with the  $gfap^{\Delta 560ins24}$  mutant allele, 178 but for the examined phenotypes in the  $gfap^{4460}$  allele we observed similar phenotypes (Fig. 179 S3). 180

The eyes of  $gfap^{+/-}$  and  $gfap^{-/-}$  larval showed a reduction in size at six days post fertilization 181 (dpf), but not earlier, without affecting the body length (Fig. 4a-b' and Fig. S4a-b'). Rescue 182 experiments with human WT and c.928dup GFAP mRNA demonstrated that WT GFAP 183 mRNA ( $hGFAP^{WT}$ ), but not c.928dup mRNA rescued the eve size phenotype (Fig. 4c, c'). 184 Sagittal sections of the gfap mutant larvae showed normal cells layers in the retina, but at 6 185 dpf revealed a significant decrement in cells of the ganglion cell layer (GCL), inner nuclear 186 187 layer (INL) and photoreceptor layer (Fig. 4d, e). Similarly, in adult fish the retina was smaller in gfap mutant fish due to thinner GCL, INL and outer segment (OS) (Fig. 4d, f). An 188 increment in apoptosis in the inner layers of the eye and around the lens was observed in the 189

mutants as early as 52 hours post fertilization (hpf), which could contribute to the reductionin eye size (Fig. 4g).

We hypothesized that the structural changes in eye morphology in mutants might cause 192 vision impairment. We tested visual behaviour for zebrafish  $gfap^{+/-}$  and  $gfap^{-/-}$  mutants and 193 wildtype siblings, by determining reflective behaviour to sudden changes in the light 194 conditions (startle response) and reflective ability to position themselves stably in their 195 environment (optomotor response (OMR)). The startle response protocol consisted of seven 196 light to dark switches (Fig. 6a). During the testing period we observed that the distance 197 travelled by  $gfap^{+/-}$  and  $gfap^{-/-}$  larvae was less than their WT siblings (Fig. 5a and Fig. S5) 198 and, importantly, less than 75% on average of the mutant larvae exhibited a startle response 199 as compared to over 90% observed in WT siblings (Fig. 5b). We observed similar indication 200 of vision impairment when assessing the OMR of  $gfap^{+/-}$  and  $gfap^{-/-}$  larvae, which showed 201 increased inactivity and decreased duration of high-velocity swimming, when compared to 202 203 WT siblings (Fig. 5c). Together, the behaviour assays support that the vision of the mutant larvae is impaired. 204

GFAP expression was previously identified in RNPs at early developmental stages and in 205 MGCs at later stages in embryos obtained from S. canicula (small-spotted catshark)<sup>5</sup>. We 206 investigated if GFAP loss affects MGCs and RNPs during retinogenesis in zebrafish. To 207 assess this, gfap mutants were BrdU-labelled from 55 hpf shortly after the first appearance of 208 Gfap expressing MGCs to 80 hpf, after cell proliferation is restricted to the  $CMZ^{25,26}$ . The 209 BLBP marker was used to label both progenitors in the CMZ and MGCs<sup>27,28</sup>. During the time 210 211 of BrdU labelling, the MGC formation was not significantly affected, however a reduction in BrdU labelled cell area at the CMZ was apparent without change in BLBP<sup>+</sup> progenitor cell 212 area (Fig. 6a-c'). In contrast, at 6 dpf, a reduction in BLBP<sup>+</sup> progenitor cell area was observed 213

concurrently with reduced PCNA<sup>+</sup> cells at the CMZ (Fig. 6a, c' and d). This suggests that
GFAP is necessary for normal cell proliferation and maintenance of progenitor pool at the
CMZ but not the initial MGC proliferation and formation after initial retinogenesis.

A visible reduction in BLBP<sup>+</sup> MGCs at the INL and a change in morphology accompanied by a general reduction in BLBP fluorescence intensity levels at the ONL and OS was observed in the  $gfap^{+/-}$  and  $gfap^{-/-}$  mutants both in larvae and adult fish (Fig. 6e, f, f' and Fig. S4c, d). In mutant larvae, the MGCs that remained in the INL had reduced cell body area, thin processes and fewer apical branches at the base of rods and cones in the ONL/OS and adult sections showed evidence of tearing (Fig. 6e). Together this suggests that MGCs in the *gfap* mutants become dysfunctional during postembryonic growth of the eye.

Progenitors in the CMZ and MGCs are responsible for generation and maintenance of rod, cone and other neuronal lineages in the fish eye after initial retinogenesis is completed, while MGCs in the mammalian eye have a role in retinal homeostasis<sup>8,26,29</sup>. Given the observed MGC phenotypes in  $gfap^{+/-}$  and  $gfap^{-/-}$  mutants, we examined rod and double cone development during early postembryonic development and in the adult eye<sup>30</sup>.

We observed a significant reduction in  $Zpr3^+$  rods and double cones in *gfap* mutants at 6 dpf 229 and in juvenile and adult fish (Fig. 6g-i and Fig. S4c', d', e), but not earlier. Although non-230 primates like zebrafish do not have a macular region, they have regions with high 231 photoreceptor density similar to the human macular<sup>31</sup>. To determine whether Zpr3<sup>+</sup> 232 photoreceptor loss occurred at a pituitary macular region, we estimated the region relative to 233 the optic nerve in our *gfap* mutants after performing 3D reconstruction of whole juvenile (14 234 dpf) and adult eyes (9 mpf). In gfap mutant juvenile eyes, visibly fewer photoreceptors in the 235 pituitary macular region were observed than around the optic nerve and periphery regions 236 (compared to WT siblings) (Fig. 6g). In contrast, Zpr3<sup>+</sup> photoreceptor cell loss was observed 237

both in the periphery regions and the pituitary macular region of adult  $gfap^{+/-}$  and  $gfap^{-/-}$  eyes,

with  $gfap^{-/-}$  being more affected than  $gfap^{+/-}$  (Fig. S6).

240 In summary, clinical and genetic analyses of patients revealed a rare GFAP variant associated

- 241 with a novel human eye phenotype. Expression analyses and *in vivo* experiments supported a
- 242 previously unknown role of GFAP in retinal development.

# 243 **DISCUSSION**

#### 244 Identification of a novel inherited optico-retinal dysplasia

The current study reports on a six-generation family with a unique hereditary optic nerve head dysplasia that was examined in six individuals from the last three generations. The eye disorder was characterized by intra- and pre-papillary glia-like tissue extending along the retinal vessels and involving the central retina with edema and atrophy of the retinal pigment epithelium (RPE) of the macula. OCT demonstrated extensive optic nerve head gliosis with accumulation of intra-papillary amorphous substance and fluorescein angiography (not shown) showed leakage from the capillary system in the macular area.

Pre-papillary and peri-papillary glia-like structures representing a variety of developmental 252 253 anomalies are common findings in clinical ophthalmology. Among these persistent hyperplastic primary vitreous (PHPV)<sup>32,33</sup> and Bergmeister papilla<sup>34</sup> are well known clinical 254 entities. The majority of developmental prepapillary and preretinal tissue formations is 255 unilateral and sporadic, however may also be found in hereditary systemic disorders as 256 neurofibromatosis type  $2^{35}$  and familial exudative vitreoretinopathy<sup>36</sup>. PHPV and Bergmeister 257 papilla are considered the result of a deficient regression of the primary hyaloid artery 258 system, however, hypovascular glial overgrowth from the optic nerve head in foetuses 259 indicates that non-vascular mechanisms also exist<sup>37</sup>. Combined hamartoma of the retina and 260 retinal pigment epithelium<sup>38,39</sup> shows similarity to the optico-retinal disorder described here, 261

which however, had no sign of a hamartoma of the macular pigment epithelium. Similar clinical findings were described in a family showing autosomal dominant inheritance in three generations reported at the ARVO Annual Meeting in  $2010^{40}$ . Clinical examination of six affected family members from that family showed variable phenotypes with different degrees of fibro-glial proliferation over the optic discs and peripapillary area and various degrees and retinal pigment epithelium disruption and migration. A genetic analysis for causative variants in *NF2* was negative.

The described optico-retinal dysplasia is to our best knowledge the first eye disorder without systemic involvement associated with a variant in the glial fibrillary acidic protein (GFAP), a classical marker of glial cells, among which astrocytes have crucial functions in retinal development.

# 273 Human GFAP expression pattern in RNP and MGCs suggest an evolutionary conserved 274 role of GFAP in retinal development

In our study we examined GFAP expression during early human retinal development. 275 Previous studies indicated that GFAP is expressed during human fetal retina development 276 from 8 wpc but similar to the postnatal development in mice its expression was observed only 277 in astrocyte precursors that had migrated to the optic nerve head<sup>4,41-44</sup>. In contrast, our 278 findings demonstrate that robust GFAP expression is present in RNPs throughout the retina 279 of the developing human fetal eye already at 35 dpc. Furthermore, our findings suggest that 280 GFAP expression intensifies during astrocyte precursor maturation and migration into the 281 282 vascularized central retina beginning at 13 wpc which is earlier than previously estimated (16-18 wpc)<sup>42,45</sup>. Interestingly at 51 dpc we observed strong GFAP expression at the 283 periphery of the developing neural retina near the ciliary body. The gradual weakening of 284 285 GFAP expression in RNPs with radial orientation and changes in cell morphology with RNPs differentiation is characteristic of the CMZ. The ability of CMZ to generate retinal cells 286

during development has been thought to be lost in mammals<sup>26,46–48</sup>. However, a recent study 287 in mice demonstrated that Cyclin  $D2^+$  and  $Msx1^+$  cells from the ventral embryonic CMZ can 288 become retinal ganglion cells<sup>49</sup> and all seven cell types in the eye<sup>50</sup>, respectively. Our results 289 suggest that a subgroup of RNPs in the developing human eye matures into MGCs resulting 290 in significant downregulation of GFAP expression with retained expression at distal 291 processes and end-feet. The observed appearance of mature MGCs at 13 wpc is in agreement 292 with a recent report dating it to 12 wpc<sup>51</sup>. To the best of our knowledge, a functional CMZ 293 and GFAP expression in RNPs have not previously been demonstrated in primates, but 294 appear to resemble the GFAP immunoreactivity pattern observed in the CMZ of embryonic 295 catshark fish (S. canicula). In catshark fish, Gfap expression occurs in the pre-neurogenic 296 retina in neural stem cells, which during the neurogenic developmental stage elongate and 297 transform into MGCs when RNP change to an asymmetric mode of cell division<sup>5</sup>. 298

# 299 GFAP c.928dup does not cause extensive protein aggregation in vivo

Genetic analysis of the affected individuals demonstrated that the disorder segregates with a variant in *GFAP* (c.928dup; p.Met310Asnfs\*113) causing a frameshift and incorporation of 112 aberrant amino acids resulting in a partial deletion of the 2B rod domain. The observed dysplasia was stationary across decades in the examined individuals. Affected individuals were in good health, with none of the classical indications of severe AxD with the exception of mild difficulties in swallowing, which can be found in the clinical spectrum of  $AxD^{13}$ .

AxD is a heterogeneous disease that can be mild or even asymptomatic despite remarkable atrophy of the brainstem and spinal cord on MRI<sup>52</sup>. In fact, a nonsense mutation variant in proximity of our variant has been reported to cause a mild and atypical case of AxD (c.1000G>T, p.E312\*)<sup>14,53</sup>. Overexpression of GFAP without the tail domain has previously been reported to form polymorphic aggregates<sup>54,55</sup>. However, the GFAP variant

p.Met310Asnfs\*113 has a large number of out-of-frame amino acids, and thus the outcome 311 312 of this variant is unpredictable. Furthermore, GFAP aggregation and AxD outcome is complicated by the expression of different GFAP isoforms and mis-splicing in humans, 313 which are difficult to model in animals<sup>56,57</sup>. Several isoforms of GFAP exist in humans, 314 however, not all of them are translated into protein product<sup>58</sup>. Two isoforms ( $\Delta$ exon6 and 315  $\Delta 135$ ) are expected not to be affected by the c.928dup variant, and consequently may 316 contribute to the mild clinical signs in the affected individuals. Lastly, at present we cannot 317 rule out that the c.928dup GFAP variant produces transcripts that undergo nonsense-318 mediated-decay (NMD) in the affected individuals<sup>59,</sup> but since the novel stop-codon is only 319 320 31 nucleotides from the wild type GFAP stop-codon (and in the same exon) we find NMD unlikely. Taken together, we cannot exclude the possibility that the affected individuals with 321 the optico-retinal dysplasia represent asymptomatic cases of AxD. However, given that the 322 p.Met310Asnfs\*113 variant does not result in extensive GFAP aggregation and the disease 323 progression is largely stationary in the affected individuals, we find this scenario unlikely. 324

325

# 326 Retinal dysplasia-like phenotype in zebrafish gfap mutants

To examine the consequence of gfap loss-of-function, we generated a promoter-less mutant 327 to abolish potential genetic compensation<sup>24</sup>. Several studies of *GFAP* null mice reported 328 normal development, growth, fertility and lifespan<sup>60-64</sup>. Although obvious candidates for 329 compensation (such as Vimentin and Nestin) were ruled out<sup>61,65,66</sup>, recent studies in 330 331 vertebrates have proven genetic compensation to be more complex, for instance as the result of degradation of mutant mRNA and upregulation of genes with sequence homology to 332 mutant mRNA<sup>24,67</sup>. Characterisation of our zebrafish promoter-less *gfap* mutants revealed a 333 previously uncharacterized small-eye phenotype and visual impairment at post-embryonic 334 stages. Cell proliferation changes at the germinal zone located all around the retinal margin 335 and cell shrinkage may influence neurogenesis and retina size in the larvae and adult fish<sup>68</sup>. 336 Our data suggest reduced cell proliferation at the CMZ is the main contributor to the 337 phenotype in *gfap* mutants. MGCs in the fish eye proliferate at low rates to produce neural 338 progenitors during postembryonic development of fish retina<sup>29</sup> and provide tensile strength<sup>69</sup>, 339 suggesting that the MGC phenotype in gfap mutants could contribute to the observed small-340 eye phenotype and photoreceptor loss. However, the initial MGC formation was not affected 341 in the mutants probably due to the intact BLBP<sup>+</sup> progenitor pool in the CMZ. In contrast, 342 later in development MGC phenotypes were evident concurrently with a depletion in the 343 progenitor pool at the CMZ. This indicates that loss of MGCs is a secondary effect to CMZ 344 dysfunction occurring after initial retinogenesis is completed. These MGCs displayed smaller 345 soma with abnormal processes and branching at the ONL, with weaker BLBP fluorescence 346 intensity. In the brain, *Blbp* transcription is induced in radial glia by migrating neurons 347 through Notch signalling and blocking BLBP function in radial glia causes a reduction in the 348 number of radial processes extended<sup>27,40</sup>. Abnormally compressed, thin and dysfunctional 349

350 MGCs, have previously been observed in stressed retina of Gfap and Vimentin knockout 351 mice<sup>70</sup>.

352 Concurrently with abnormal BLBP marker levels in MGCs, photoreceptor outer segment loss as well as thinning of retinal layers in aging fish. Photoreceptor apoptosis and changes in 353 retinal layer thickness and intraretinal neovascularization has previously been observed in 354 studies utilizing conditional ablation techniques to ablate MGCs in adult mice $^{71,72}$ . 355 Abnormalities in the inner retinal layer and the foveal containing high density of 356 photoreceptors were similarly observed in the majority of OCTs from the examined affected 357 358 individuals. However, the zebrafish gfap mutants did not show any sign of a vascularized epiretinal glial mass at the optic nerve and no salient deficiency was observed in BLBP<sup>+</sup> 359 retinal astrocytes at the GCL and nerve fibre layer. The absence of developmental defects at 360 the optic nerve may be attributed to the fact that unlike mammals, zebrafish astrocytes of the 361 optic nerve and many other fish species express Gfap transiently or not at all<sup>73,74</sup>. 362 Furthermore, the progressive nature of the phenotype observed in the gfap mutant fish may 363 be attributed to the fact that retinas of postembryonic teleost fish develop faster and exhibit 364 continuous growth in the retina over their entire lifetime, while the human eye is 365 morphologically fully developed by 2-3 years of life<sup>28,75,76</sup>. 366

In conclusion, this work identifies a GFAP mutation causing optico-retinal dysplasia and vision impairment likely through haploinsufficiency or a dominant negative mechanism. We further demonstrate that RNPs during human retinogenesis express GFAP and that uncompensated loss of GFAP in zebrafish results in detrimental changes for MGCs and photoreceptors. The role for GFAP as a contributor to early retinogenesis calls for care when designing clinical studies and therapeutic approaches aiming to abate GFAP function in AxD patients.

- 374
- 375
- 376
- 377

# 378 MATERIAL AND METHODS

# 379 Antibodies and PCR primers table

GC
ũ
Ĵ
1
GACGCATCAC
TTGTGCTCC
indideree
CAGGAGGAGC
CTGCCTCTC
CCATGGGGC
AGAGGTCAT
AUAUUICAI

380

381

382

# 383 Family pedigree and clinical investigations

The pedigree encompassed six generations, the first three individuals were known to be visually impaired by history only, three were followed for a period of 35 years. All available patient files were retrieved and scrutinized and a re-investigation of five affected, one unaffected, and one non-penetrant individual was made. Re-examinations took place at the Department of Ophthalmology, Rigshospitalet, Copenhagen.

Standard ophthalmological examination was performed in all seven individuals including best corrected visual acuity (BCVA) according to the ETDRS procedure. The subjects underwent fundus photography (Topcon), spectral-domain-optic coherence tomography (SD-OCT) (Heidelberg Eye Explorer) including autofluorescence photography, one of the subjects had fluorescence angiography, indocyanine green angiography, adaptive optics, and full-field ERG.

Written informed consent was obtained from all participants. The study was approved by the National Committee on Health Research Ethics, Denmark (journal number 1301394) and followed the tenets of the Declaration of Helsinki.

# 398 Molecular genetic analysis

Blood samples were obtained for eight family members (IV-4, IV-6, V-1, V-3, V-7, V-8, VI3, VI-4) and high molecular DNA was extracted using the Chemagic 360 machine (Perkin
Elmer, Waltham, Massachusetts, USA). Whole genome sequencing was performed by BGI
Group (Shenzhen, China) using Illumina HiSeq X-ten. A mean coverage of 30 X were

403 provided. Alignment was performed to NCBI hg19 version of the human genome using BWA 404 software. GATK (Broad Institute, MIT Harvard, Cambridge, MA, USA) was used for variant calling (SNV and indels). Three affected (V-1, V-3, V-7) and one unaffected (VI-3) 405 406 individual were analyzed. A total of 398,394 unique variants were retrieved for the four samples. The VarSeq program (Golden Helix, Bozeman, Montana, USA) was used for 407 filtering. Coding variants (including 8 bp flanking intron sequence) with a minor allele 408 frequency (MAF) below 0.5% in the gnomAD v2.1.1 409 database (https://gnomad.broadinstitute.org/) and an allelic frequency between 0.3 and 0.7 were 410 411 retrieved. The zygosity of affected individuals were set to heterozygous whereas the unaffected individual was set to reference. The Alamut Visual Plus program (Lausanne, 412 Switzerland and Boston, Massachusetts, USA) were used for further analysis of variants. 413

(5'-414 Segregation analysis was performed using primers GFAP-ex6-FH acccactgcttactggcttatcGAGATGCCAGGGGGAGAAGG-3') GFAP-ex6-RH (5'-415 and gaggggcaaacaacagatggcCAGGGCCAGCTTGACATTG-3') for PCR amplification and 416 subsequent Sanger sequencing. Capital letters are gene specific and small letters are used for 417 subsequent sequencing. Sequencing was performed using BigDye v3.2 terminators (Applied 418 419 Biosystems, Waltham, Massachusetts, USA) and analysis on an ABI3130XL (Applied Biosystems). 420

Details of the primary antibodies including dilutions and suppliers are listed in Antibodies and PCR primers table. Control sections were incubated with mouse IgG1 or irrelevant rabbit antibodies, as well as subjected to omission of primary or secondary antibodies. These were always blank.

#### 425 Immunohistochemistry of human embryonic and fetal eyes

Four human embryos and 5 fetuses were obtained from legal abortions after informed consent
from all contributing women following oral and written information, in accordance with the
Helsinki Declaration II, and was approved by the Danish Regional Committee on Health
Research Ethics (KF–V.100.1735/90) & (KF-11 2006 – 4838).

Immediately following the abortion, entire embryos of 35 dpc, 51 dpc and 53 dpc (days post 430 431 conception) and fetal eyes from fetuses of 13, 15 and 19 wpc (weeks post conception) were removed and promptly fixed for 12–24 h at 4 °C in either 10% neutral buffered formalin, 4% 432 formol-calcium, Lillie's or Bouin's fixatives. This procedure kept the time from delivery to 433 fixation at a minimum, normally less than 2 h, in order to retain optimal tissue quality. Prior 434 to paraffin embedding, the specimens were dehydrated with graded alcohols, and cleared in 435 xylene. Then 3 - 6 µm thick serial sections were cut in transverse, sagittal or horizontal 436 planes, and placed on silanized glass slides. 437

Sections were deparaffinized and rehydrated in xylene following standard protocols. 438 Endogenous peroxidase was quenched using a 0.5% solution of hydrogen peroxide in TBS 439 440 for 15 minutes. Following rinses with TRIS buffered saline (TBS, 5 mM Tris-HCl, 146 mM NaCl, pH 7.6), non-specific binding was inhibited by incubation for 30 minutes with 10% 441 goat serum at room temperature. The sections were incubated overnight at 4°C with primary 442 antibodies (Antibodies and PCR primers table) diluted in blocking buffer and washed with 443 TBS. For bright field light microscopy analysis, the REAL EnVision Detection System 444 (Peroxidase/DAB+ rabbit/mouse, code K5007, DakoCytomation, Glostrup, Denmark) was 445 used for detecting mouse and rabbit primary antibodies. The sections were washed with TBS. 446 Positive staining was recognized as a brown color. The sections were counterstained with 447 toluidine blue or Mayers hematoxylin and dehydrated in graded alcohols and coverslipped 448 with Pertex mounting media. 449

#### 450 Zebrafish husbandry

The AB Wild-type (WT) zebrafish strain was obtained from the Zebrafish International Resource Center (ZIRC) and maintained in the animal facility of the University of Copenhagen. The WT were raised at 28°C and kept in a constant LD cycle according to standard protocols. All experiments and animal handling procedures were approved and conducted under licenses from the Danish Animal Experiments Inspectorate (Protocol code: P18-120/P20-387).

# 457 Generation of promoter-less gfap mutants

The promoter motifs of the zebrafish gfap promoter were mapped using the Eukaryotic 458 promoter database (https://epd.epfl.ch/). Based on the location of the motifs, crRNAs were 459 designed and evaluated using the IDT CRISPR design (Integrated DNA Technologies) tool. 460 A pair of crRNAs was selected with a target region upstream of the 5' UTR (IDT Design ID: 461 CD.Cas9.JPYK4256.AC) and downstream of the gfap start-codon, respectively (IDT Design 462 ID: Dr.Cas9.GFAP.1.AL). The CRISPR-Cas9 ribonucleoprotein complex was assembled 463 464 according to the manufacturer's protocol for zebrafish embryo microinjections. Briefly, equimolar amounts of crRNAs and tracrRNA were mixed in a nuclease-free duplex buffer to 465 create a 3 µM gRNA complex solution. The gRNA solution complex was mixed with an 466 equal volume of 0.5 µg/µL HiFi Cas9 Nuclease V3 (IDT) protein solution diluted in Cas9 467 working buffer (20 mM HEPES-KOH, 150 mM KCl, pH 7.5). The gRNA/Cas9 mixture was 468 incubated at 37°C for 10 min to assemble the ribonucleoprotein complex. Microinjections 469 were performed using a pressurized injection system (Intracel, Picospritzer III) with needles 470 pulled from filamented capillaries (WPI) on a Sutter Instrument P30-867 guided by an 471 Intracel M-152 micromanipulator. Injection droplets were calibrated to  $\sim$ 125 µm diameter at 472 473 the start of injection, resulting in approx. 1 nl injection mix delivered into the cytoplasm of

one-cell staged embryos. Experiments were done using F2 and subsequent generations.Primers used for genotyping and sequencing are listed in Antibodies and PCR primers table.

# 476 Eye diameter measurements

Measurements of the left and right eye width were conducted blindly from Z-series of mRNA
injected (100 pg) and uninjected heterozygous in-crosses from different pairs at 2 and 6 dpf.
The Z-series were collected with a Zeiss Axio Zoom.V16 microscope equipped with a
AxioCam 705 color camera (Interval thickness: 5.0 µm) from individual larvae anesthetized
in 0.02% tricaine methanesulfonate (Sigma-Aldrich, A5040) and mounted in 3 %
methylcellulose.

# 483 Total RNA isolation and qRT-PCR

To determine the degree of endogenous *gfap* promoter silencing in the promoter-less mutants, 484 RNA was extracted from a pool of homozygous outcrosses, and in-crosses of wildtype sibling 485 486 and homozygous from three different pairs using the RNA isolation kit (Zymo Research). One microgam of total RNA was reverse transcribed using SuperScript<sup>TM</sup> II (Invitrogen, 487 Carlsbad, CA), and oligo-dT primers (Invitrogen). To detect gfap cDNA (NM 131373.2), 488 489 qRT-PCR was performed using Brilliant III Ultra-Fast SYBR® Green qPCR master mix (Agilent Technologies) with the primers 5'-GGATGCAGCCAATCGTAAT-3' (forward) and 490 5'-TTCCAGGTCACAGGTCAG-3' (reverse). The qRT-PCR reactions were performed in 491 triplicate and were analyzed on an ABI 7500 fast system. The data was normalized against 492 the average expression value of the housekeeping gene  $\beta$ -actin2. 493

#### 494 Western Blot

495 Prior to protein extraction, microinjected larvae (30 hpf) were manually dechorinated,
496 anesthetized and deyolked in Deyolking buffer (55mM NaCl, 1.8mM KCl, 1.25mM

NaHCO<sub>3</sub>) at 1100 rpm. Devolked larvae were collected at 3000rpm, 4°C and rinsed several 497 498 times in Wash buffer (110mM NaCl, 3.5mM KCl, 10mM Tris pH 8.5, 2.7mM CaCl<sub>2</sub>). The larvae were subsequently lysed in Protein extraction buffer (1% SDS and 10mM Tris pH 7.4) 499 500 with proteinase inhibitors and flash-freezed. Western blot was carried out as previously described in Schrøder et al., 2011 using horseradish peroxidase-conjugated secondary 501 antibodies. Blots were developed with FUSION-Fx chemiluminescence system (Vilber 502 Lourmat) while images were processed and analysed in Photoshop CS6 and ImageJ (Fiji), 503 respectively. Primary antibodies for western blot and immunofluorescence are listed in 504 Antibodies and PCR primers table. 505

# 506 Cloning of GFAP fusion and transcription of mRNA from full-length constructs

The GFAP p.Met310Asnfs\*113 fusion construct was cloned by site-directed mutagenesis of 507 the mini-Tol2 vector containing the human WT GFAP construct1 introducing the nucleotide 508 duplication at position 928. Subsequently another round of site-directed mutagenesis was 509 performed to remove the stop-codon generated by the frameshift and the remaining ORF. For 510 511 mRNA generation the GFAP cDNA was amplified from a universal human cDNA library (Takara Bio) and subcloned into the pCS2+ vector using the XhoI/SnaBI sites. The c.928dup 512 mutation was introduced by site-directed mutagenesis with the full-length vector as 513 previously described for the fusion construct. Capped mRNA was generated in vitro after 514 NotI linearization with the mMESSAGE mMACHINE Kit (ThermoFisher) kit and purified 515 according to manufactures instructions. All plasmids were verified by DNA sequencing 516 (ABI3130xl Genetic Analysers). Primers used for cloning are listed in Antibodies and PCR 517 primers table. 518

# 519 **GFAP aggregation assay**

520 The GFAP aggregation assay was performed as previously described1. Briefly, expression 521 vectors containing the WT, p.Arg79Cys and p.Met310Asnfs\*113 GFAP construct were microinjected into the cytoplasm of one-cell staged zebrafish embryos (50 pg). At 30 hpf the 522 523 embryos were anesthetized and mounted in 3% methylcellulose for imagining. Z-series of the head and trunk regions were collected (Interval thickness: 4.0 µm) with a Zeiss Axio 524 Zoom.V16 microscope equipped with a AxioCam 705 color camera. GFAP aggregates were 525 blindly counted using the Cell Counter plugin in ImageJ (Fiji). Representative stacking 526 images were assembled in ZEN 3.2 Pro (Zeiss) and Photoshop CS6 software (Adobe). 527

#### 528 Sectioning, H&E and immunofluorescence of the fish eye

For sectioning, 2, 4 and 6 dpf zebrafish larvae from heterozygous in-crosses were collected 529 530 and fixed in 4% paraformaldehyde (PFA) overnight at 4 °C. Larvae were rinsed in PBS, genotyped and their heads embedded and orientated in 5% agarose. Genotyped adult fish 531 were fixed in 4% PFA for several days at 4°C after anesthetizing and euthanizing the fish. 532 533 The eyes were carefully enucleated, embedded and orientated in 5% agarose. The agarose 534 blocks were dehydrated in increasing alcohol solutions over several days (70%/96%/99% EtOH). Following dehydration of the agarose block, the block was transferred into Xylene 535 and into paraffin overnight at 60 °C. The block was embedded into fresh paraffin prior to 536 sectioning and slide collection (Sagittal sectioning, thickness: 5 or 7 µm). Slides with the 537 sections were dried overnight at 37 °C followed by standard haematoxylin and eosin or 538 immunofluorescence (IF) staining using secondary antibodies coupled with Alexa488 539 (Invitrogen, 1:100) or RedX (1:100, Jackson ImmunoResearch) and nuclear stained with 540 DAPI. Haematoxylin and eosin-stained slides were imaged on AxioScan 7 slide scanner 541 (Zeiss) and IF-stained slides were imaged on LSM710 confocal system (Zeiss). 542

### 543 TUNEL assay

For the TUNEL assay, embryos were fixed in 4% paraformaldehyde for 2 hours at room temperature and kept in 100% methanol overnight at -20°C. After gradual rehydration and genotyping, apoptotic cells were detected using the ApopTag peroxidase in situ apoptosis detection kit (Millipore). The samples were mounted in glycerol and Z-series of the right eye was collected (interval thickness: 3.0 μm) with Axio Zoom.V16 microscope equipped with a AxioCam 705 color camera (Zeiss).

# 550 BrdU incorporation assay

BrdU injections were performed as done previously<sup>8</sup>. Briefly, 55 hpf larvae were lightly anaesthetized in E3 medium (0.05% MS-222; Sigma) and immobilized on an agarose plate. The larvae were subsequently microinjected into the middle of the yolk sac with 1.5 nL of 10mM BrdU in 15% DMSO/sterile saline solution. Injected embryos were returned to E3 medium and grown at 28°C until the time of fixation (80 hpf) and subsequently processed for ECi-DEEP tissue clearing.

# 557 ECi-DEEP-Clear of the zebrafish eye

The clearing protocol for the eye was adapted from the DEEP-Clear protocol<sup>77</sup>. Unless 558 otherwise stated the pH for solutions were neutral (pH 7-7.4). Zebrafish samples were first 559 anesthetized with 0.04% tricaine methanesulfonate (Sigma-Aldrich, A5040) and euthanized. 560 This was followed by immediate fixation in 4% paraformaldehyde at 4°C for 1-3 days and 561 562 removal of fixative by rinsing in PBS several times at room temperature. For adult fish, eyes were carefully enucleated and dehydrated in pre-chilled acetone overnight at -20°C. Juvenile 563 (and younger) fish were decapitated post-fixation and the whole head processed. After 564 acetone treatment, samples were pre-treated with 3% H<sub>2</sub>O<sub>2</sub> in Acetone for 30min at room 565

566 temperature and gradually rehydrated in 75%, 50% and 0% acetone in PBS. In juvenile and adult eye samples, guanine crystals in the eye were dissolved by long rinses in PBS pH  $6.0^{78}$ . 567 After several short dH<sub>2</sub>O rinses, samples were first depigmented by bleaching in 3% 568 569 H<sub>2</sub>O<sub>2</sub>/1% KOH for approx. 45 min to 4 hours under strong light, followed by hydrophilic depigmentation in 8% THEED (Sigma-Aldrich, 87600) and 5% Triton-X in PBS pH 9-10, at 570 571 37°C for 30 min to 2 days. Depigmentation durations were dependent on the developmental stage of the eye. After several PBS rinses, unspecific antibody binding was blocked in PBDT 572 (1% DMSO, 1% BSA, 0.1% Tween20, 0.5% Triton X-100, 5% goat serum, PBS) and 573 samples incubated with primary antibodies in PBDT overnight at 4°C (Antibodies and PCR 574 575 primers table). Unbounded antibodies were subsequently removed by several PBSTT (0.1% Triton-X, 0.1% Tween20, PBS) rinses at room temperature and incubated with secondary 576 antibodies coupled to Alexa488, Alexa647 (Invitrogen, 1:100) or RedX (1:100, Jackson 577 ImmunoResearch) in PBDT overnight at 4°C. Following several PBSTT rinses, the samples 578 were nuclear stained with SYTOX Deep Red Nucleic Acid Stain (Thermo Scientific, 579 580 S11381) or DAPI at room temperature and mounted in 2% low-melting agarose. Samples were then gradually dehydrated in 20%, 40%, 60%, 80%, 96% and 99% ethanol in dH<sub>2</sub>O (pH 581 9-10) at room temperature and immediately RI matched in ethyl cinnamate (Sigma-Aldrich, 582 8.00238) prior to imaging. Larvae and juvenile samples were imaged on a Zeiss CellObserver 583 Spinning Disk confocal system using a Plan-Apochromat 20x/0.8 M27 objective or Zeiss 584 Lsm900 using a Plan-Apochromat 40x/1.4 objective. Adult samples were imaged on Zeiss 585 Light Sheet 7 using a Plan Apo 10x/0.5 objective. Deconvolution and correction of chromatic 586 aberrations (if any) was done using Huygens Professional software (Scientific Volume 587 588 Imaging).

#### 589 Startle response and optomotor response (OMR) assay

590 Prior to conducting the assay, fed larvae were cultured in a light environment for at least 1 591 hour. For startle response assessment, 7 dpf larvae were carefully transferred to a 48-well plate with 1 mL E3 medium. The plate was inserted into the Zebrabox (Viewpoint, France) 592 593 allowing the fish to readapt to the equipment light conditions before subjected to seven Light-Dark cycles (including the light adaptation step) during the motion tracking. Dark duration 594 was set to 1 second and light duration was set to 30 seconds. The overall activity of the larvae 595 was recorded in one second-bins for a total duration of 3 minutes and 7 seconds following 596 light-adaptation. Unresponsive larvae were defined as larvae moving less or equal to 0.1 mm 597 per second during light to dark switches. For OMR, 9 dpf larvae were carefully transferred to 598 a 10 well OMR plate (Viewpoint, France) with E3 medium. Adaptation to a white 599 background (bottom screen) and lighting conditions was done for at least 30 minutes inside 600 the Zebrabox (Viewpoint, France). Subsequently the background was changed into moving 601 black horizontal stripes on a white background (10 stripes, 30 rpm, 25 fps) and fish 602 locomotion was recorded for 5 minutes in 5 second bins. Swim speed was recorded in four 603 604 categories: Fast (>8 mm/s), intermediate (3-8 mm/s) and slow (<3 mm/s) and no activity (no 605 detection of movement). For all experiments light adaptation inside the Zebrabox and "Light periods" were set to 12 % power (Top Light) and "Dark periods" to 0 %, with an infrared 606 illumination and camera recording at 60 frames per second. The detection sensitivity level 607 was set to 21 and minimum size to 3, which focuses the movement detection on the head of 608 each larva and ignores movement of smaller particles. 609

610 Q

#### Quantification and data analysis

Quantification of MGCs number and soma area in IF paraffin tissue sections was done
blindly using the Cell Counter plugin in ImageJ (Fiji) and by randomly selecting six MGCs
per section for manual area measurements. Cell of the GCL was counted from sections

614 located near the middle of the eye using the Cell Counter plugin in ImageJ (Fiji), while the cell number for the other layers was estimated based on area measurements. BrdU<sup>+</sup> and 615 BLBP<sup>+</sup> area measurements and PCNA<sup>+</sup> cell counts in the dorsal and ventral CMZ were 616 617 quantified from optical sections in the middle of the eye. ZPR3<sup>+</sup> cell number, signal volume and fluorescence intensity were quantified in IF sections or whole eyes samples by extracting 618 statistical data from spot or surface function in Imaris (Bitplane, UK). IF data analysis of 619 proliferative MGCs was performed on 3D reconstructions of whole eye samples from BrdU 620 labelled larvae using Imaris (Bitplane, UK). MGCs were counted as proliferative when 621 double labelled with Alexa647 (BrdU) and RedX (BLBP) signal. In whole eyes of juvenile 622 and adult ZPR3<sup>+</sup> volume estimation was done on 3D reconstructions using Imaris (Bitplane, 623 UK). Thickness for each layer in the adult eye was estimated as the mean of three 624 measurements in fixed ROIs positioned dorsal, posterior and ventral to the lens in 625 haematoxylin and eosin-stained sections of 7 mpf eyes. Data analysis from IF or 626 haematoxylin and eosin-stained paraffin sections, was performed on 3-4 consecutive or near-627 consecutive sections for each fish (at least 3 fish). For IF sections of the adult fish eye, a 700 628 x 700 µm ROI near the lens for each section was used for data analysis. For whole eye 629 sampling, n=3-5 eyes from 3-5 fish (interval thickness: 0.2-0.5 µm) or 12 consecutive optical 630 sections for each genotype (3 fish; interval thickness:  $5.0 \,\mu\text{m}$ ) was used for data analysis. The 631 pituitary macular region in 3D reconstructed eyes in the figures was estimated based on 632 human eye anatomy<sup>79</sup>, at a fixed angle (17 degrees) with a distance of 2.5 times the optic 633 nerve diameter from the optic nerve (14 dpf<sup>+/+;+/-;-/-</sup>: 63.4, 59.9 and 60.6  $\mu$ m; 9 mpf<sup>+/+;+/-;-/-</sup>: 634 716.7, 733.8 and 682.6 µm). 635

# 636 **DECLARATION OF INTERESTS**

637 The authors declare no competing interests.

# 638 AUTHOR CONTRIBUTIONS

- 639 MVKS, TR, LAL and KG conceived the study. LAL, KG, STC and KM supervised
- 640 experiments. MVKS, LAL and KG wrote the manuscript with input from all authors (MVKS,
- 641 CR, SB, YA, LK, STC, KB-N, KM, TR, LAL and KG). CR, LK and TR performed clinical
- analyses. CJ and KG performed genetic analysis. MVKS, SB and YA performed zebrafish
- 643 experiments and analyses. KM performed immunohistochemistry on fetal human sections.

# 644 ACKNOWLEDGEMENTS

645 We are grateful to the patients and their family members for agreeing to participate in this

646 study. We would like to thank Pernille Froh, Ha Nguyen and Pia Skovgaard for expert

technical assistance. We acknowledge the Core Facility for Integrated Microscopy, Faculty of

Health and Medical Sciences, University of Copenhagen. The study was supported by grants

649 from the Velux Foundation, the Novo Nordisk Foundation and the Carlsberg Foundation.

650

# 651 **REFERENCES**

652	1.	Messing, A. & Brenner, M. GFAP at 50. ASN Neuro 12, (2020).
653 654	2.	Tao, C. & Zhang, X. Development of astrocytes in the vertebrate eye. <i>Dev Dyn</i> <b>243</b> , 1501–10 (2014).
655 656 657	3.	Holst, C. B., Brøchner, C. B., Vitting-Seerup, K. & Møllgård, K. Astrogliogenesis in human fetal brain: complex spatiotemporal immunoreactivity patterns of GFAP, S100, AQP4 and YKL-40. <i>J Anat</i> 235, 590–615 (2019).
658 659 660	4.	Sarthy, P. V., Fu, M. & Huang, J. Developmental Expression of the Glial Fibrillary Acidic Protein (GFAP) Gene in the Mouse Retina. Cellular and Molecular Neurobiology vol. 11 (1991).
661 662	5.	Sánchez-Farías, N. & Candal, E. Identification of radial glia progenitors in the developing and adult retina of sharks. <i>Front Neuroanat</i> <b>10</b> , (2016).
663 664 665	6.	Julian, D., Ennis, K. & Korenbrot, J. I. Birth and fate of proliferative cells in the inner nuclear layer of the mature fish retina. <i>Journal of Comparative Neurology</i> <b>394</b> , 271–282 (1998).
666 667	7.	Otteson, D. C., D'Costa, A. R. & Hitchcock, P. F. Putative stem cells and the lineage of rod photoreceptors in the mature retina of the goldfish. <i>Dev Biol</i> <b>232</b> , 62–76 (2001).

668 669 670	8.	Nelson, S. M., Frey, R. A., Wardwell, S. L. & Stenkamp, D. L. The developmental sequence of gene expression within the rod photoreceptor lineage in embryonic zebrafish. <i>Developmental Dynamics</i> <b>237</b> , 2903–2917 (2008).
671 672	9.	Mack, A. F., Papanikolaou, D. & Lillo, C. Investigation of the migration path for new rod photoreceptors in the adult cichlid fish retina. <i>Exp Neurol</i> <b>184</b> , 90–96 (2003).
673 674	10.	Fischer, A. J. & Reh, T. A. Müller glia are a potential source of neural regeneration in the postnatal chicken retina. <i>Nat Neurosci</i> <b>4</b> , 247–52 (2001).
675 676	11.	Brenner, M. <i>et al.</i> Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. <i>Nat Genet</i> <b>27</b> , 117–20 (2001).
677 678 679	12.	Hagemann, T. L. Alexander disease: models, mechanisms, and medicine. <i>Current Opinion in Neurobiology</i> vol. 72 140–147 Preprint at https://doi.org/10.1016/j.conb.2021.10.002 (2022).
680 681	13.	Messing, A. Alexander disease. in <i>Handbook of Clinical Neurology</i> vol. 148 693–700 (Elsevier B.V., 2018).
682 683 684	14.	Nam, T. S. <i>et al.</i> Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease. <i>European Journal of Human Genetics</i> <b>23</b> , 72–78 (2015).
685 686 687	15.	Messing, A. Refining the concept of GFAP toxicity in Alexander disease. <i>Journal of Neurodevelopmental Disorders</i> vol. 11 Preprint at https://doi.org/10.1186/s11689-019-9290-0 (2019).
688 689	16.	Hagemann, T. L. <i>et al.</i> Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. <i>Ann Neurol</i> <b>83</b> , 27–39 (2018).
690 691 692	17.	Hagemann, T. L. et al. Antisense Therapy in a Rat Model of Alexander Disease Reverses GFAP Pathology, White Matter Deficits, and Motor Impairment. Sci. Transl. Med vol. 13 https://www.science.org (2021).
693 694	18.	Bustamante-Marin, X. M. <i>et al.</i> Lack of GAS2L2 Causes PCD by Impairing Cilia Orientation and Mucociliary Clearance. <i>Am J Hum Genet</i> <b>104</b> , 229–245 (2019).
695 696 697	19.	Richards, S. <i>et al.</i> Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genet Med</i> <b>17</b> , 405–24 (2015).
698 699 700 701 702 703 704 705	20.	ClinGen The Clinical Genome Resource. Heidi L. Rehm, Ph.D., Jonathan S. Berg, M.D., Ph.D., Lisa D. Brooks, Ph.D., Carlos D. Bustamante, Ph.D., James P. Evans, M.D., Ph.D., Melissa J. Landrum, Ph.D., David H. Ledbetter, Ph.D., Donna R. Maglott, Ph.D., Christa Lese Martin, Ph.D., Robert L. Nussbaum, M.D., Sharon E. Plon, M.D., Ph.D., Erin M. Ramos, Ph.D., Stephen T. Sherry, Ph.D., and Michael S. Watson, Ph.D., for ClinGen. N Engl J Med 2015; 372:2235-2242 June 4, 2015 DOI: 10.1056/NEJMsr1406261 https://clinicalgenome.org/working-groups/sequence- variant-interpretation/.
706 707	21.	Kim, S. J. <i>et al.</i> Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. <i>Hum Genet</i> <b>129</b> , 497–502 (2011).
708 709	22.	Brunkow, M. E. <i>et al.</i> Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. <i>Am J Hum Genet</i> <b>68</b> , 577–589 (2001).

710	23.	Lee, S. H. et al. Aggregation-prone GFAP mutation in Alexander disease validated
711		using a zebrafish model. <i>BMC Neurol</i> <b>17</b> , (2017).
712 713	24.	El-Brolosy, M. A. <i>et al.</i> Genetic compensation triggered by mutant mRNA degradation. <i>Nature</i> <b>568</b> , 193–197 (2019).
714 715	25.	Bernardos, R. L. & Raymond, P. A. GFAP transgenic zebrafish. <i>Gene Expression Patterns</i> 6, 1007–1013 (2006).
716 717	26.	Fischer, A. J., Bosse, J. L. & El-Hodiri, H. M. The ciliary marginal zone (CMZ) in development and regeneration of the vertebrate eye. <i>Exp Eye Res</i> <b>116</b> , 199–204 (2013).
718 719 720	27.	Anthony, T. E., Mason, H. A., Gridley, T., Fishell, G. & Heintz, N. Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. <i>Genes Dev</i> <b>19</b> , 1028–1033 (2005).
721 722 723	28.	Raymond, P. A., Barthel, L. K., Bernardos, R. L. & Perkowski, J. J. Molecular characterization of retinal stem cells and their niches in adult zebrafish. <i>BMC Dev Biol</i> <b>6</b> , 36 (2006).
724 725 726	29.	Bernardos, R. L., Barthel, L. K., Meyers, J. R. & Raymond, P. A. Late-stage neuronal progenitors in the retina are radial Müller glia that function as retinal stem cells. <i>Journal of Neuroscience</i> <b>27</b> , 7028–7040 (2007).
727 728	30.	Yin, J. <i>et al.</i> The 1D4 antibody labels outer segments of long double cone but not rod photoreceptors in zebrafish. <i>Invest Ophthalmol Vis Sci</i> <b>53</b> , 4943–4951 (2012).
729 730	31.	Noel, N. C. L., MacDonald, I. M. & Allison, W. T. Zebrafish Models of Photoreceptor Dysfunction and Degeneration. <i>Biomolecules</i> <b>11</b> , 1–33 (2021).
731 732	32.	Zhu, M., Provis, J. M. & Penfold, P. L. The human hyaloid system: cellular phenotypes and inter-relationships. <i>Exp Eye Res</i> <b>68</b> , 553–63 (1999).
733 734 735	33.	Goldberg, M. F. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. <i>Am J Ophthalmol</i> <b>124</b> , 587–626 (1997).
736 737	34.	Mehta, A., Singh, S. R., Dogra, M. & Ram, J. Persistent fetal vasculature - Clinical spectrum. <i>Indian J Ophthalmol</i> <b>66</b> , 1860 (2018).
738 739 740	35.	Sisk, R. A., Berrocal, A. M., Schefler, A. C., Dubovy, S. R. & Bauer, M. S. Epiretinal membranes indicate a severe phenotype of neurofibromatosis type 2. <i>Retina</i> <b>30</b> , S51-8 (2010).
741 742 743	36.	Xiao, H., Tong, Y., Zhu, Y. & Peng, M. Familial Exudative Vitreoretinopathy-Related Disease-Causing Genes and Norrin/β-Catenin Signal Pathway: Structure, Function, and Mutation Spectrums. <i>J Ophthalmol</i> <b>2019</b> , 5782536 (2019).
744 745	37.	Azuma, N., Hida, T. & Kohsaka, S. Hypovascular glial overgrowth from the optic nerve head in foetuses of 16 weeks gestation. <i>Acta Ophthalmol</i> <b>87</b> , 355–7 (2009).
746 747 748	38.	Gass, J. D. M. An unusual hamartoma of the pigment epithelium and retina simulating choroidal melanoma and retinoblastoma. 1973. <i>Retina</i> <b>23</b> , 171–83; discussion 184-5 (2003).

749 750 751	39.	Shields, C. L. <i>et al.</i> Combined hamartoma of the retina and retinal pigment epithelium in 77 consecutive patients visual outcome based on macular versus extramacular tumor location. <i>Ophthalmology</i> <b>115</b> , 2246-2252.e3 (2008).
752 753 754	40.	Hester CC, Imes RK, Lujan BJ & Fu AD. Autosomal dominant bilateral combined hamartoma of the retina and retinal pigment epithelium or a new familial optic nerve dysgenesis? <i>Invest. Ophthalmol. Vis. Sci.</i> <b>51</b> , 3546 (2010).
755 756 757	41.	Božanić, D., Bočina, I. & Saraga-Babić, M. Involvement of cytoskelatal proteins and growth factor receptors during development of the human eye. <i>Anat Embryol (Berl)</i> <b>211</b> , 367–377 (2006).
758 759 760	42.	Chu, Y., Hughes, S. & Chan-Ling, T. Differentiation and migration of astrocyte precursor cells (APCs) and astrocytes in human fetal retina: relevance to optic nerve coloboma. <i>The FASEB Journal</i> <b>15</b> , 2013–2015 (2001).
761 762	43.	Huxlin, K. R., Sefton, A. J. & Furby, J. H. The origin and development of retinal astrocytes in the mouse. <i>J Neurocytol</i> <b>21</b> , 530–544 (1992).
763 764 765	44.	Dorrell, M. I., Aguilar, E. & Friedlander, M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. <i>Invest Ophthalmol Vis Sci</i> <b>43</b> , 3500–10 (2002).
766 767	45.	Mellough, C. B. <i>et al.</i> An integrated transcriptional analysis of the developing human retina. <i>Development (Cambridge)</i> <b>146</b> , (2019).
768 769	46.	Wetts, R., Serbedzija, G. N. & Fraser, S. E. Cell lineage analysis reveals multipotent precursors in the ciliary margin of the frog retina. <i>Dev Biol</i> <b>136</b> , 254–63 (1989).
770 771	47.	Johns, P. R. Growth of the adult goldfish eye. III. Source of the new retinal cells. <i>J Comp Neurol</i> <b>176</b> , 343–57 (1977).
772 773	48.	Fischer, A. J. & Reh, T. A. Identification of a proliferating marginal zone of retinal progenitors in postnatal chickens. <i>Dev Biol</i> <b>220</b> , 197–210 (2000).
774 775	49.	Marcucci, F. <i>et al.</i> The Ciliary Margin Zone of the Mammalian Retina Generates Retinal Ganglion Cells. <i>Cell Rep</i> <b>17</b> , 3153–3164 (2016).
776 777 778	50.	Bélanger, MC., Robert, B. & Cayouette, M. Msx1-Positive Progenitors in the Retinal Ciliary Margin Give Rise to Both Neural and Non-neural Progenies in Mammals. <i>Dev Cell</i> <b>40</b> , 137–150 (2017).
779 780 781	51.	Bulirsch, L. M. <i>et al.</i> Spatial and temporal immunoreaction of nestin, CD44, collagen IX and GFAP in human retinal Müller cells in the developing fetal eye. <i>Exp Eye Res</i> <b>217</b> , (2022).
782 783 784 785	52.	Sugiyama, A. <i>et al.</i> Incidental diagnosis of an asymptomatic adult-onset Alexander disease by brain magnetic resonance imaging for preoperative evaluation. <i>Journal of the Neurological Sciences</i> vol. 354 131–132 Preprint at https://doi.org/10.1016/j.jns.2015.05.001 (2015).
786 787	53.	Brenner, M. & Messing, A. A new mutation in GFAP widens the spectrum of Alexander disease. <i>Eur J Hum Genet</i> <b>23</b> , 1–2 (2015).

788 789 790	54.	Quinlan, R. A., Moir, R. D. & Stewart, M. Expression in Escherichia coli of fragments of glial fibrillary acidic protein: characterization, assembly properties and paracrystal formation. <i>J Cell Sci</i> <b>93</b> ( <b>Pt 1</b> ), 71–83 (1989).
791 792	55.	Chen, W. J. & Liem, R. K. The endless story of the glial fibrillary acidic protein. <i>J Cell Sci</i> <b>107</b> ( <b>Pt 8</b> ), 2299–311 (1994).
793 794 795 796	56.	Perng, MD. <i>et al.</i> Glial fibrillary acidic protein filaments can tolerate the incorporation of assembly-compromised GFAP-delta, but with consequences for filament organization and alphaB-crystallin association. <i>Mol Biol Cell</i> <b>19</b> , 4521–33 (2008).
797 798	57.	Flint, D. <i>et al.</i> Splice site, frameshift, and chimeric GFAP mutations in Alexander disease. <i>Hum Mutat</i> <b>33</b> , 1141–1148 (2012).
799 800 801	58.	van Asperen, J. V, Robe, P. A. J. T. & Hol, E. M. GFAP Alternative Splicing and the Relevance for Disease - A Focus on Diffuse Gliomas. <i>ASN Neuro</i> <b>14</b> , 17590914221102064 (2022).
802 803	59.	Maquat, L. E. Nonsense-mediated mRNA decay in mammals. <i>J Cell Sci</i> <b>118</b> , 1773–1776 (2005).
804 805	60.	Gomi, H. et al. Mice Devoid of the Glial Fibrillary Acidic Protein Develop Normally and Are Susceptible to Scrapie Prions. Neuron vol. 14 (1995).
806 807 808 809	61.	Mccall, M. A. et al. Targeted Deletion in Astrocyte Intermediate Filament (Gfap) Alters Neuronal Physiology (Long-Term Potentiation/Hippocampus/Optic Nerve/Homologous Recombination/Mouse). Neurobiology vol. 93 https://www.pnas.org (1996).
810 811 812	62.	Pekny, M. <i>et al.</i> Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. <i>EMBO Journal</i> <b>14</b> , 1590–1598 (1995).
813 814	63.	Nawashiro, H., Messing, A., Azzam, N. & Brenner, M. Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injury. <i>Neuroreport</i> <b>9</b> , 1691–6 (1998).
815 816 817	64.	Shibuki, K., Gomi, H. & Chen, L. Deficient Cerebellar Long-Term Depression, Impaired Eyeblink Conditioning, and Normal Motor Coordination in GFAP Mutant Mice. Neuron vol. 16 (1996).
818 819 820	65.	Triolo, D. <i>et al.</i> Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. <i>J Cell Sci</i> <b>119</b> , 3981–3993 (2006).
821 822 823	66.	Kamphuis, W. <i>et al.</i> GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. <i>Glia</i> <b>63</b> , 1036–1056 (2015).
824 825	67.	Rossi, A. <i>et al.</i> Genetic compensation induced by deleterious mutations but not gene knockdowns. <i>Nature</i> <b>524</b> , 230–233 (2015).
826 827	68.	Fernald, R. D. Teleost vision: Seeing while growing. <i>Journal of Experimental Zoology</i> <b>256</b> , 167–180 (1990).

828 829	69.	MacDonald, R. B. <i>et al.</i> Müller glia provide essential tensile strength to the developing retina. <i>Journal of Cell Biology</i> <b>210</b> , 1075–1083 (2015).
830 831	70.	Verardo, M. R. <i>et al.</i> Abnormal reactivity of muller cells after retinal detachment in mice deficient in GFAP and vimentin. <i>Invest Ophthalmol Vis Sci</i> <b>49</b> , 3659–65 (2008).
832 833	71.	Shen, W. <i>et al.</i> Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. <i>J Neurosci</i> <b>32</b> , 15715–27 (2012).
834 835	72.	Byrne, L. C. <i>et al.</i> AAV-Mediated, Optogenetic Ablation of Müller Glia Leads to Structural and Functional Changes in the Mouse Retina. <i>PLoS One</i> <b>8</b> , e76075 (2013).
836 837	73.	Maggs, A. & Scholes, J. Glial domains and nerve fiber patterns in the fish retinotectal pathway. <i>J Neurosci</i> <b>6</b> , 424–38 (1986).
838 839 840	74.	Conrad, M., Lemb, K., Schubert, T. & Markl, J. Biochemical identification and tissue- specific expression patterns of keratins in the zebrafish Danio rerio. <i>Cell Tissue Res</i> <b>293</b> , 195–205 (1998).
841 842	75.	van Cruchten, S. <i>et al.</i> Pre- and Postnatal Development of the Eye: A Species Comparison. <i>Birth Defects Res</i> <b>109</b> , 1540–1567 (2017).
843 844	76.	Harris, W. A. & Perron, M. Molecular recapitulation: the growth of the vertebrate retina. <i>Int J Dev Biol</i> <b>42</b> , 299–304 (1998).
845 846	77.	Pende, M. <i>et al.</i> A versatile depigmentation, clearing, and labeling method for exploring nervous system diversity. <i>Sci Adv</i> <b>6</b> , eaba0365 (2020).
847 848 849	78.	Kimura, T. <i>et al.</i> Guanine crystals regulated by chitin-based honeycomb frameworks for tunable structural colors of sapphirinid copepod, Sapphirina nigromaculata. <i>Sci Rep</i> <b>10</b> , (2020).
850 851	79.	Kolb, H. Simple Anatomy of the Retina. Webvision: The Organization of the Retina and Visual System (1995).
852		
853		
854		
855		
856		
857		
858		
859		

### 860 FIGURES & FIGURE LEGENDS



861

#### 862 Figure 1. Mutation of GFAP is associated with retinal dysplasia and vision loss.

a. Pedigree of a family with an autosomal dominant optical dysplasia with retinal 863 involvement and vision loss. Affected individuals are shown with black fill symbols and 864 unaffected with open symbols. The affected individuals V-1, V-3, V-7, VI-4 and an obligate 865 carrier IV-6 were heterozygous for a c.928dup variant (m) in GFAP, while three unaffected 866 individuals (IV-4, V-8 and VI-3) were found not to be carriers (wt). b. Clinical data. The 867 fundoscopic phenotype showed varied degrees of gliosis of the optic nerve head resulting in a 868 dome-shaped pellucid epiretinal veil and blurring of the disc margins (left panel, showing 869 right and left eye). Subretinal fluid was observed. Three of the affected individuals (IV-1, V-870 3, and V-7) presented a massive glia-like mass covering the optic disc resembling 871 pseudopapilledema as shown by Macular- and optic nerve OCT (Right panel). c. DNA 872 sequence of *GFAP* nucleotide c.916-934 from a healthy (control) and an affected (c.928dup) 873 individual. 874

875



#### 876

# 877 Figure 2. GFAP is expressed in human retinal neural progenitors.

a-b. Sagittal section of human eye anlage at 35 dpc. a. Toluidine blue stained section. a'. 878 879 Nestin (NES) immunostaining marks retinal neural progenitors (RNPs) in the NL. b, b', b''. Immunostaining shows strong expression of GFAP in RNPs within the NL. c. Sagittal section 880 of human eye at 51 dpc. GFAP immunostaining shows strong expression in early RNPs 881 882 (black arrow), and weaker expression in more differentiated RNPs (grey arrows). d-f. Sagittal section of human eye at 13 wpc. Immunostaining show very weak GFAP expression (d, e, 883 884 arrows) in MGC, marked by Vimentin (VIM) expression (f, arrows), but very strong GFAP expression in astrocytes, entering the retina from the optic nerve. LV: lens vesicle, LE: lens, 885 886 NL: nervous layer, ON: optic nerve, PL: pigment layer, RE: retina, RPE: retinal pigment epithelium, VC: vitreous cavity. 887

- 888
- 889
- 890
- 891


Figure 3. The p.Met310Asnfs\*113 variant protein have similar aggregation properties as WTGFAP in vivo.

892

a. Diagram of the injected expression plasmid encoding human GFAP C-terminally fused to a 895 896 FLAG epitope and EGFP driven by a zebrafish gfap promoter. pGFAP: zebrafish gfap promoter; hGFAP: human GFAP; F: 3× FLAG epitope tag; eGFP: enhanced green 897 fluorescent protein and pA: polyadenylation sequence (a, top). High-magnification dorsal 898 view ROI images of the head and trunk for each injected larvae group, scale bar: 100  $\mu$ m (a, 899 bottom). a'. Quantification of GFAP aggregates in the brain and spinal cord of 30 hpf and 48 900 hpf larvae microinjected with 50 pg GFAP(WT), GFAP(p.Met310Asnfs\*113) or 901 902 GFAP(R79C) fusion construct (30 hpf: n=30 larvae for each genotype; 48 hpf: n=6 larvae for each genotype). **b.** Western blot analysis with GFP, zebrafish Gfap and GAPDH antibodies 903 of the same injected groups as in (a); antibodies and protein size calculation as indicated. The 904

905	data is prese	ented as	mean±sd.	Asterisks	indicate	P-values	obtained	by using	g One-way
906	ANOVA	test:	****:	Р	< 0.	.0001,	ns:	not	significant.



# Figure 4. Zebrafish promoter-less *gfap* mutants have smaller eyes which can be rescued with WT but not c.928dup mRNA.

a. Dorsal view images of 2 and 6 dpf larvae head of WT and *gfap* mutant siblings with or 910 without injection of 100pg WT gfap mRNA or c.928dup mRNA (as indicated). White bars 911 912 indicate an approximation of the major axis diameter for comparison. Scale bar: 50 µm. Measured mean diameter of both eyes for uninjected 2 dpf (b) 6 dpf (b') larvae (n=17-32 and 913 n=33-80 for each genotype, respectively) and 6 dpf larvae injected with WT (c) and c.928dup 914 mRNA (c') (n=10-26 and n=10-24 for each genotype, respectively). **d.** Hematoxylin and 915 eosin staining of WT and gfap mutant siblings eyes at different stages: 2, 4 and 6 dpf and 916 seven months post fertilization (mpf, adult fish), scalebar: 50 µm and scale bar: 500 µm, 917 respectively (**d**, top). Higher magnification of retinal layers in 7 mpf fish. GCL, ganglion cell 918 layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, 919 920 outer nuclear layer; OS, outer segments; RPE, retinal pigment epithelium, scale bar: 50 µm. (d, bottom). e. Quantification of cells in the GCL, INL and photoreceptor layer from 4 and 6 921 922 dpf WT and gfap mutant sibling retina sections. **f.** Mean layer thickness in 7 mpf retina sections. g. TUNEL assay of 36 hpf and 52 hpf eyes in the same group of WT and gfap 923 mutant siblings (n=4-8 and n=4-7 for each genotype, respectively), scale bar: 100  $\mu$ m (g, top). 924 Quantification of apoptotic events in the eye of the same group (g, bottom). The data are 925 presented as mean±sd. Asterisks indicate P-values obtained by using One-way ANOVA test: 926 \*: P < 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001, \*\*\*\*: P < 0.0001, ns: not significant. 927 928



## 931 Figure 5. *Gfap* promoter-less mutants are visually impaired.

932 **a.** Startle-response assay. Diagram of the 3 minutes and 7 seconds testing protocol following adaptation to light consisting of seven dark periods and six light each with a duration of 1 933 934 second and 30 second, respectively (a, top). Plot of the mean distance travelled by 7 dpf WT and mutant siblings over the testing phase (n=48-96) (a, bottom left). Bar plot of the mean 935 maximum swim speed achieved during light switches (a, bottom right). b. Distribution of the 936 937 mean larvae number that respond to light switches (b, left). One-way ANOVA test of the percentage responsive larvae during all the cycles (**b**, right). **c.** OMR. Bar plot of the duration 938 spend at different swim speed: no activity, slow (<3mm/s), intermediate (3-8 mm/s) and fast 939 940 (>8mm/s) (n=15-45) (c, top). Representative locomotion of five 9 dpf larvae color-coded for swim speed (slow: black, intermediate: green, fast: red) for WT and gfap mutant siblings (c, 941 bottom). Data is presented as mean±sd. Asterisks indicate P-values obtained by using One-942 way ANOVA test: \*: P < 0.05, \*\*\*\*: P < 0.0001, ns: not significant. 943



Figure 6. MGCs, rods and double cones are abnormal in *gfap* promoter-less mutants. 946 The BLBP marker was used to label progenitors in the CMZ and MGCs<sup>27,28</sup>. **a.** IF maximum 947 projection of BLBP<sup>+</sup> MGCs and BrdU<sup>+</sup> cells in the center of the eve from 80 hpf WT siblings 948 and *gfap* mutants ( $\mathbf{a}$ , top). White lines indicate the BLBP<sup>+</sup> CMZ area. IF maximum projection 949 950 of CMZ PCNA<sup>+</sup> cells in the center of the eye from 6 dpf WT siblings and gfap mutants ( $\mathbf{a}$ , bottom). Scalebar 50 µm. b. Bar plot of percent BLBP<sup>+</sup> and BrdU<sup>+</sup> MGCs in 80 hpf whole 951 eves from WT siblings and gfap mutant. c. Bar plot of percent  $BrdU^+$  area normalized to 952 CMZ BLBP<sup>+</sup> area. c'. Bar plot of mean CMZ BLBP<sup>+</sup> area (dorsal and ventral) measured in 953 sections from 80 hpf and 6 dpf WT siblings and *gfap* mutants. **d.** Bar plot of percent PCNA<sup>+</sup> 954 cells of total DAPI<sup>+</sup> cells in the retina of 6 dpf WT siblings and *gfap* mutant retinal sections. 955 e. IF maximum projection of BLBP<sup>+</sup> MGCs in 6 dpf (e, top) and 7 mpf (e, bottom) WT and 956 gfap mutant retina. White lines indicate the  $BLBP^+$  CMZ area in 6 dpf retina. Higher 957 958 magnification of MGCs at INL in ROI (white boxes). White arrowheads indicate weak BLBP expression in MGC soma and apical processes at OS. Blue arrowheads indicate tearing with 959 no DAPI staining in adult retina (e, bottom). f-f'. Bar plot of the MGC count and 960 measurements of soma area of MGCs in 4 and 6 dpf retinas from the same group of fish. g. IF 961 maximum projection of Zpr3<sup>+</sup> rods and double cone outer segment of 4 dpf, 6 dpf and 7 mpf 962 WT and mutant retina (g, top and middle). Higher magnification of  $Zpr3^+$  rods and double 963 cone outer segment in ROI (white boxes). 3D reconstruction of juvenile (14 dpf) eyes stained 964 for  $Zpr3^+$  rods and cones (g, bottom). White circle highlights the pituitary macular region of 965 the eye. **h-h'.** Bar plots of  $Zpr3^+$  cell number and volume in 4 and 6 dpf sections and 7 mpf 966 from the same group of fish. i. Bar plot of  $Zpr3^+$  cell volume in sections and whole eyes, 967 respectively. Scalebars: 50 µm (80 hpf, 4 and 6 dpf). Scalebars: 100 µm (14 dpf and 7 mpf). 968 969 Data analysis from sections and whole eyes is n=9-12 sections and n=3-5 eyes for each genotype, respectively. Data is presented as mean±sd. Asterisks in plots indicate P-values 970 obtained by using One-way ANOVA test: \*\*: P < 0.01, \*\*\*: P < 0.001, \*\*\*\*: P < 0.0001, ns: 971 not significant. 972



### 973 SUPLEMENTAL FIGURES & FIGURE LEGENDS



- 975 Figure S1. Analysis of the zebrafish gfap promoter and sequence of gfap promoter-less mutants.
- **a.** Diagram of the *Danio rerio* (zebrafish) *gfap* promoter (ENSDARG0000025301) from -500 to +300 and result of *in silico* analysis of
- 977 promoter motifs in the same region with a cut-off p-value of: 0.001. **b**, left. Comparison of the *gfap* promoter and coding sequence from -499 to
- +300 in WT, gfap<sup> $\Delta 460$ </sup> and gfap<sup> $\Delta 560$ ins<sup>24</sup></sup> promoter-less mutants. Underlined and bold text shows exon and insertion sequence, respectively. **b**,
- 979 right. Chromatogram obtained with forward sequencing primer and the sequence obtained from the reverse sequencing primer in the affected
- 980 regions of the same fish lines.



981

982 Figure S2. Silencing gfap promoter in promoter-less zebrafish mutants result in no detectable983 Gfap protein.

**a.** Relative expression of zebrafish *gfap* mRNA in 3 dpf gfap<sup> $\Delta 460$ </sup> and gfap<sup> $\Delta 560ins24$ </sup> promoterless mutants and WT siblings quantified by qRT-PCR (n=2-4 for each genotype). b-c'. IF maximum projection of Gfap<sup>+</sup> MGC endfeet and processes, as well as astrocytes in 6 dpf gfap<sup> $\Delta 460$ </sup> (b,b') and gfap<sup> $\Delta 560ins24$ </sup> (c,c') WT and mutant retina. Scalebar, 50 µm.





991 a. Dorsal view images of 6 dpf larvae head of uninjected WT and mutant siblings. White bars indicate an approximation of the major axis diameter for comparison, scale bar: 50 µm. a'. 992 Measured mean diameter of both eyes for uninjected 6 dpf larvae ( $n_{WT}=20$ ,  $n_{+/-}=64$ ,  $n_{-/}=26$ ). 993 a". Bar graph of measured larva body length of the fish shown in a'. b. IF maximum 994 projection of BLBP<sup>+</sup> MGCs and ZPR3<sup>+</sup> rods and double cone outer segment in the OS of 4 995 dpf and 6dpf retinas from mutant and WT siblings. Scale bar: 50 µm. b'. Bar plot of the 996 MGC count per 5µm section (n=9 for each genotype). b'. Quantification of soma area of 997 MGCs in 4 and 6 dpf retinas from the same group of fish as shown in (b) (n=9 for each 998 999 genotype). c. Hematoxylin and eosin staining of WT and mutant siblings eye sections at different stages: 2, 4 and 6 dpf. The data are presented as mean±sd. Asterisks indicate P-1000

1001 values obtained by using One-way ANOVA test: \*: P < 0.05, \*\*: P < 0.01, \*\*\*\*: P < 0.0001,

1002 ns: not significant.



1004 **Figure S4.** Additional data for  $gfap^{\Delta 560ins24}$  promoter-less mutants.

- **a-b'.** Bar graph of measured larva body length of uninjected 2 dpf (a), 6 dpf uninjected (a') and injected with 100pg WT gfap mRNA (b) or
- 1006 c.928dup mRNA (b') in mutants and WT siblings group shown in Figure 4. c-d'. Bar graphs of BLBP (c, d) and ZPR3 (c',d') signal intensities
- 1007 measured in the ONL and OS layer of the eyes from 4 and 6 dpf as well as 7 mpf mutants and their WT siblings fish (n=4 for each genotype). e.
- 1008 Bar graph of ZPR3 signal intensities measured in eyes from 14 dpf mutants and WT siblings fish (n=5 for each genotype).



1009



1011 Representative locomotion of sixteen 7 dpf gfap $^{\Delta 560 \text{ins} 24}$  promoter-less mutants and their WT

siblings. Red lines indicate the movement of the individual larva in each well during the time

1013 recorded.





**Figure S6.** Rods and double cone outer segment of  $gfap^{\Delta 560 \text{ins} 24}$  promoter-less adult fish eyes.

**1017 a-a''.** Brightfield pictures of adult eyes from 9 mpf WT siblings (a) and gfap<sup> $\Delta$ 560ins24</sup>

1018 promoter-less mutant fish (a',a'') (not to scale). **b-b''.** 3D reconstruction of the retina stained

1019 for ZPR3<sup>+</sup> rods and double cones in the same group of fish eyes (posterior view), scale bar

 $300 \mu m$ . White circle highlights the pituitary macular region of the eye.

## 1029 SUPLEMENTAL TABLES

Position in	IV-6	V-1	V-3	V-7
pedigree Genotype	c.[928dup];[=]	c.[928dup];[=]	c.[928dup];[=]	c.[928dup];[=]
GFAP <sup>a</sup>				
BCVA		1982: RE: 1,25 (+0,75 -2,0 x 80°) LE: 1,25 (+0,75 -1,75 x 150°)	1982: RE: 0,3 (+3,5 -2,25 x 80°) LE: 0,25 (+4,5 -1,0 x 145°) 2003: RE: 0,4 (+2,75 -2,25 x 70°) LE: 0,3 (+3,25 -1,0 x 90 °)	1981: RE:0,25 (+0,75) LE: 0,16 (-1,0 -2,0 x 0°) 2005: RE: 0,16 (+1,5 -2,25 x 170°) LE: 0,16 (+2,0 -2,75 x 5°)
Fundoscopic <sup>b</sup>	Normal looking optic nerve head, retina, and vascular system	Pre- and peripapillary pellucid veil, normal optic nerve head, macular region and normal vessels	Massive pre-and peripapillary glial mass with sheeting of arterioles extending along the arcades. Distinct macular RPE atrophy in both macular regions	Pellucid pre- and peripapillary glial mass, massive central and peripheral vascular sheeting with a few splint hemorrhages. Diffuse RPE atrophy in the macular regions with pigment clumping.
Goldmann	Normal	Normal	Central scotoma both	Central scotoma both eyes
perimetry			eyes	
Colour vision	NA	NA	Normal	Normal
Fullfield ERG	NA	NA	Normal	Normal
OCT		Abnormal morphology of optic disc. No signs of drusen. Extension of the epiretinal glial mass to macular region. Disorganized inner retinal layer	Abnormal morphology of optic disc. No signs of drusen. Extension of the epiretinal glial mass to macular region. Disorganized inner retinal layer. Atrophic retina in foveal region.	Abnormal morphology of optic disc. No signs of drusen. Extension of the epiretinal glial mass to macular region. Disorganized inner retinal layer. Atrophic retina in foveal region.
Fluorescein angiography 1974/2018		NA	NA	Vascularized epipapillary glial mass
Systemic signs		None	None	None

**Table S1.** Clinical and genetic data on family.

<sup>a</sup> GFAP NC\_000017.11, NM\_002055.5 (GRCh38). WT: normal sequence in GFAP position
 c.928. <sup>b</sup> No retinal dragging was observed in any of the affected individuals. BCVA: best
 corrected visual acuity. NA: not applied. RE: right eye; LE: left eye.

1034

#### **1036 Table S2.** Rare variants shared by affected family members.

1037 Three affected individuals (V-1, V-3 and V-7) and one unaffected individual (IV-4) was analyzed using whole genome sequencing. Rare variants

1038 present in all three affected individuals, but not in the unaffected individual is shown.

Gene	Chr location (GRCh37)	Transcript	Protein	Population frequency <sup>a</sup>	Consequence	Classification <sup>b</sup>	Disease association of gene
PEMT	17:17494884	NM_148172.2: c.57T>C	NP_680477.1: p.Pro19=	7.15e-04	Synonymous	n/a	n/a
OR10H2	19:15839201	NM_013939.2: c.348C>T	NP_039227.1: p.Thr116=	1.79e-04	Synonymous	n/a	n/a
GAS2L2	17:34074257	NM_139285.3: c.863C>T	NP_644814.1: p.Pro288Leu	8.77e-04	Missense	VUS (PM2_sup, BP4_mod)	Biallellic variants associated with primary ciliary dyskinesia (MIM #618449) <sup>18</sup>
SOST	17:41836027	NM_025237.2: c.83C>T	NP_079513.1: p.Ala28Val	2.73e-05	Missense	VUS (BP4_sup)	Monoallellic variants associated with Craniodiaphyseal dysplasia (MIM #122860) <sup>21</sup> . Biallelic variants associated with Sclerosteosis 1 (MIM #269500) <sup>22</sup>
GFAP	17:42988803	NM_001242376.1: c.928dupA	NP_001229305.1: p.Met310Asnfs	n/a	Frameshift	Likely pathogenic (PVS1_mod, PM2_sup, PP1_strong)	Monoallellic variants associated with Alexander disease (MIM # 203450).

<sup>a</sup> Frequency in gnomAD v.4.0.0 (gnomad.broadinstitute.org). <sup>b</sup> Classification according to ACMG guidelines<sup>19</sup> and ClinGenome webpage<sup>20</sup>